Introduction
Kidney transplantation is the preferred intervention for patients with end-stage renal disease because it improves patient survival and quality of life (1) (2) (3) , but the donor organ supply is limited (4) (5) (6) . Expansion of the donor pool to include kidneys from older donors and/or donors with health issues (United Network for Organ Sharing [UNOS] expanded criteria donor [ECD] kidneys) has helped address growing demand. Nevertheless, recipients of kidneys that meet expanded donation criteria tend to have poorer rates of graft and patient survival compared with recipients of living donor or standard-criteria deceased donor (SCD) kidneys (2, (7) (8) (9) (10) . Moreover, patients transplanted with ECD kidneys are more likely to experience delayed graft function (DGF) and diminished allograft function (11) , resulting in increased resource utilization and a higher risk of graft loss. Although donation after cardiac death (DCD; i.e. non-heart-beating donors) kidneys are increasingly being used to help overcome organ shortages (12) , better understanding of outcomes in recipients of this donor kidney subtype is needed.
Impaired renal function, particularly GFR, at 1 year after transplant is strongly associated with reduced graft survival and a higher incidence of cardiac death (13) (14) (15) (16) (17) (18) (19) . Calcineurin inhibitors (CNIs) have been linked to declining renal function and chronic allograft nephropathy, which may eventually lead to allograft failure (20) . There is a need for effective non-CNI-based immunosuppressive regimens; however, data on non-CNI-based regimens in recipients of ECD kidneys are limited.
Belatacept is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the modified extracellular domain of CTLA4. Belatacept selectively inhibits T cell activation through costimulation blockade (21) (22) (23) (24) and is indicated for the prophylaxis of organ rejection in adult kidney transplant recipients. Its approval was based in part on the results of two phase III trials: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENE-FIT), which enrolled recipients of living donor or SCD kidneys (25) , and the BENEFIT-Extended Criteria Donors Trial (BENEFIT-EXT) (26) . BENEFIT-EXT is the largest prospective study conducted to date examining non-CNIbased immunosuppression in recipients of kidneys meeting extended donation criteria.
At 3 years after transplant in BENEFIT and BENEFIT-EXT, belatacept was associated with superior renal function to cyclosporine (CsA) and similar patient and graft survival despite higher grades (BENEFIT and BENEFIT-EXT) and higher rates (BENEFIT only) of early acute rejection (AR) (27, 28) . Post hoc analyses performed at 7 years after transplant demonstrated a significant reduction in the risk of death or graft loss among belatacept-versus CsA-treated patients in BENEFIT (29) , whereas rates of death or graft loss were similar across treatment arms in BENEFIT-EXT (30) . In BENEFIT and BENEFIT-EXT, renal function at 7 years after transplant was significantly greater in belatacept-versus CsA-treated patients (29, 30) . Over 7 years, the probability of AR was greater for belatacept-versus CsAbased immunosuppression in BENEFIT (29) ; the risk of AR was similar in belatacept-and CsA-treated patients in BEN-EFIT-EXT (30) . To better understand the efficacy and safety of belatacept across donor kidney subtypes, we conducted a post hoc analysis of 7-year data from BENEFIT-EXT.
Patients and Methods

Design and patients
BENEFIT-EXT (ClinicalTrials.gov identifier NCT00114777) was a 3-year international, randomized, partially blinded, phase III trial of de novo kidney transplant recipients aged ≥18 years. If approved by the treating physician, patients were eligible to continue study treatment beyond 3 years if they provided additional written informed consent. To remain in the study beyond 3 years, patients were required to continue with the immunosuppressive regimen to which they had been randomized. As described previously (26) , patients were transplanted with an extended criteria donation kidney, which was protocol defined as a UNOS ECD kidney, a DCD kidney or a kidney with an anticipated cold ischemic time (CIT) ≥24 h. UNOS ECD kidneys were defined as kidneys from donors aged ≥60 years or aged 50-59 years with two or more other risk factors (cerebrovascular accident, hypertension or serum creatinine >1.5 mg/dL). Because donor kidneys could have met more than one extended donation criterion, patients were placed into one of three mutually exclusive cohorts according to the following hierarchy: (i) DCD, (ii) UNOS ECD, (iii) anticipated CIT ≥24 h. Consequently, patients in the DCD cohort could have received a kidney that also met UNOS ECD criteria and/or had an anticipated CIT ≥24 h. Patients in the UNOS ECD cohort could have received a kidney that also had an anticipated CIT ≥24 h. It is important to note that CIT ≥24 h was only anticipated; therefore, patients could have received a kidney with CIT <24 h.
BENEFIT-EXT was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the ethics committee at each site. All patients provided written informed consent.
Interventions
Patients were randomized (1:1:1) to either more intensive (MI) or less intensive (LI) belatacept-based immunosuppression or to CsA-based immunosuppression. Dosing information has been published (26) . All patients received basiliximab induction, mycophenolate mofetil and corticosteroids. Use of T cell-depleting agents was permitted for anticipated DGF in CsA-treated patients at the discretion of the investigator.
The study was blinded to patients and study personnel with respect to the belatacept regimens and was open label with respect to allocation to belatacept or CsA (because of the need for therapeutic dose monitoring in CsA-treated patients). Placebo infusions were used to maintain blinding between belatacept regimens.
Statistical analysis
Analyses were performed according to intent-to-treat principles at 7 years (84 mo) after transplant for all evaluable patients. The evaluable population was composed of patients who were alive and observable at 84 mo after randomization or who had died or experienced graft loss by month 84. The statistical approaches used for this subgroup analysis mirror those used for the overall population at 7 years after transplant (30) . Briefly, time to death or graft loss was examined for each donor kidney subtype and compared for belatacept-and CsA-based treatment using a log-rank test; data were summarized using Kaplan-Meier curves and event rates. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) at month 84. The interaction between treatment and donor kidney subtype was also examined, with CsAtreated patients in the UNOS ECD cohort serving as the reference (no adjustment for multiplicity testing). Time to death and time to deathcensored graft loss were assessed as sensitivity analyses; the same statistical methods were used as for the composite analysis of time to death or graft loss, with no adjustment for multiplicity testing (30) .
Mean GFR and corresponding CIs were estimated from months 1-84 using a repeated-measures model with an unstructured covariance matrix. The model included treatment, time and a time-treatment interaction; no further adjustment was made for other potentially confounding covariates. Time was regarded as a categorical variable (intervals of 3 mo up to month 36 and intervals of 6 mo thereafter). A slope-based model without imputation was also used to determine whether there was a difference between each of the belatacept slopes and the CsA slope. The difference between slopes was tested using contrasts. In the slopebased analysis, time was regarded as a continuous variable, treatment as a fixed effect, and intercept and time as random effects; no further adjustment was made for other potentially confounding covariates. Sensitivity analyses were performed in which GFR values that were missing due to death or graft loss were imputed as zero; the same models were used as for the analyses without imputation (30) .
AR was defined as central biopsy-proven rejection that was clinically suspected either for protocol-defined reasons or for other reasons and treated. Adverse events (AEs) were mapped to terms from the Medical Dictionary for Regulatory Activities (version 17.0) and expressed as incidence rates adjusted per 100 person-years of treatment exposure. The presence of de novo donor-specific antibodies (DSAs) was assessed centrally by solid-phase flow cytometry (FLowPRA; One Lambda, Inc., Canoga Park, CA). HLA class specificity (class I or II) was determined by LABScreen single antigen beads (One Lambda, Inc.).
Results
Patient population
Patients are summarized by donor kidney subtype and treatment allocation in Figure 1 . In total, 68.9% of all randomized transplanted patients received a UNOS ECD kidney, 10.1% received a DCD kidney and 21.0% received a kidney with anticipated CIT ≥24 h. Because CIT of ≥24 h was only anticipated, 16 of the 114 patients (14.0%) in this cohort actually received a kidney with CIT <24 h. Baseline demographics and disease characteristics for each subgroup are shown in Table 1 . Data on treatment exposure and duration of follow-up are summarized in Table S1 .
Patient and graft survival
The percentages of patients assessed for death or graft loss at 84 mo after transplant in the UNOS ECD, DCD and anticipated CIT ≥24 h cohorts were 68.4% (256 of 374), 63.6% (35 of 55) and 72.8% (83 of 114), respectively. In the UNOS ECD cohort, Kaplan-Meier estimated rates of death or graft loss at month 84 for MI belatacept, LI belatacept and CsA were 35.8%, 40.1% and 41.2%, respectively. The HR for the comparison of MI belatacept with CsA was 0.839 (95% CI 0.539-1.306; p = 0.44), and the HR for the comparison of LI belatacept with CsA was 0.944 (95% CI 0.614-1.452; p = 0.79) (Figure 2A ). The corresponding Kaplan-Meier estimated rates in the DCD cohort were 39.4%, 7.7% and 48.7%, respectively. The HR for the comparison of MI belatacept with CsA was 0.722 (95% CI 0.242-2.157; p = 0.56), and the HR for the comparison of LI belatacept with CsA was 0.095 (95% CI 0.012-0.778; p = 0.0282) ( Figure 2B ). In the anticipated CIT ≥24 h cohort, Kaplan-Meier estimated rates of death or graft loss at month 84 for MI belatacept, LI belatacept and CsA were 27.9%, 30.2% and 14.9%, respectively. The HR for the comparison of MI belatacept with CsA was 1.906 (95% CI 0.651-5.576; p = 0.24), and the HR for the comparison of LI belatacept with CsA was 2.095 (95% CI 0.716-6.132; p = 0.18) ( Figure 2C ). The KaplanMeier curves for the sensitivity analyses in which time to death and time to graft loss were examined separately can be found in Figures S1 and S2, respectively. HRs and 95% CIs deriving from the interaction analysis of treatment and donor kidney subtype on time to death and/or graft loss are summarized in Table S2 .
A combined end point of time to first occurrence of death, graft loss or estimated GFR <20 mL/min per 1.73 m 2 was also examined. Kaplan-Meier estimated rates for this combined end point at month 84 in the UNOS ECD cohort were 41.6%, 43.1% and 54.0% for the MI belatacept, LI belatacept and CsA treatment arms, respectively. The HR for the comparison of MI belatacept with CsA was 0.695 (95% CI 0.471-1.024; p = 0.07), and the HR for the comparison of LI belatacept with CsA was 0.694 (95% CI 0.471-1.022;
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UNOS ECD (n=374) Figure S3B ). In the anticipated CIT ≥24 h cohort, Kaplan-Meier estimated rates of the combined end point at month 84 for MI belatacept, LI belatacept and CsA were 27.9%, 30.2% and 20.0%, respectively. The HR for the comparison of MI belatacept with CsA was 1.338 (95% CI 0.509-3.516; p = 0.55), and the HR for the comparison of LI belatacept with CsA was 1.477 (95% CI 0.562-3.882; p = 0.43) ( Figure S3C ). HRs and 95% CIs deriving from the interaction analysis of treatment and donor kidney subtype on time to this combined end point are summarized in Table S2 .
Renal function
Estimated mean GFR at month 84 ranged from 49.9 to 67.6 mL/min per 1.73 m 2 in patients treated with MI belatacept, from 50.5 to 67.6 mL/min per 1.73 m 2 in patients treated with LI belatacept and from 32.2 to 50.2 mL/min per 1.73 m 2 in patients treated with CsA ( Figure 3 ). Estimated differences in GFR significantly favored each belatacept-based regimen versus the CsAbased regimen in all three subgroups (p < 0.0001 for overall treatment effect). (95% CI 1.34-3.32) and 1.06 mL/min per 1.73 m 2 (95% CI 0.10-2.01), respectively. Relative to CsA-treated patients, the slope estimate differed significantly for patients treated with MI belatacept (p = 0.0284) but not LI belatacept (p = 0.07). Sensitivity analyses in which GFR values that were missing because of patient death or graft loss were imputed as zero yielded largely similar results ( Figure S4 ).
Rates of DGF in patients treated with MI belatacept, LI belatacept and CsA in the UNOS ECD cohort were 44.4% (56 of 126), 46.2% (55 of 119) and 42.6% (55 of 129), respectively. The corresponding rates in the DCD cohort were 55.6% (10 of 18), 47.4% (9 of 19), and 83.3% (15 of 18), respectively. In the anticipated CIT ≥24 h cohort, 50.0% (20 of 40), 51.4% (19 of 37), and 54.1% (20 of 37) of patients treated with MI belatacept, LI belatacept and CsA, respectively, experienced DGF.
Acute rejection
In the UNOS ECD cohort, Kaplan-Meier cumulative event rates of AR at month 84 for MI belatacept, LI belatacept and CsA were 24.9%, 21.8% and 15.5%, respectively. The HR for the comparison of MI belatacept with CsA was 1.650 (95% CI 0.912-2.983; p = 0.10), and the HR for the comparison of LI belatacept with CsA was 1.454 (95% CI 0.789-2.680; p = 0.23) ( Figure S5A ). In total, 28.6% (8 of 28) of MI belatacept-treated, 37.5% (9 of 24) of LI belatacept-treated and 55.6% (10 of 18) of CsA-treated patients who experienced AR also experienced death and/or graft loss. In the DCD cohort, Kaplan-Meier cumulative event rates of AR at month 84 for MI belatacept, LI belatacept and CsA were 11.9%, 21.1% and 26.3%, respectively. The HR for the comparison of MI belatacept with CsA was 0.481 (95% CI 0.088-2.629; p = 0.40), and the HR for the comparison of LI belatacept with CsA was 0.926 (95% CI 0.231-3.707; p = 0.91) ( Figure S5B ). In this cohort, 75% (3 of 4) of CsA-treated patients who experienced AR also experienced death and/or graft loss; no belatacepttreated patient experienced both AR and death/graft loss. The Kaplan-Meier cumulative event rates for MI belatacept, LI belatacept, and CsA in the anticipated CIT ≥24 h cohort were 13.3%, 11.4% and 19.3%, respectively. The HR for the comparison of MI belatacept with CsA was 0.642 (95% CI 0.204-2.024; p = 0.45), and the HR for the comparison of LI belatacept with CsA was 0.546 (95% CI 0.160-1.867; p = 0.34) ( Figure S5C ). The only patient in this cohort to experience both AR and death or graft loss was randomized to LI belatacept (25%, 1 of 4). HRs and 95% CIs deriving from the interaction analysis of treatment and donor kidney subtype on time to AR are summarized in Table S2 .
Donor-specific antibodies
In the UNOS ECD cohort, the Kaplan-Meier cumulative event rate of de novo DSAs at month 84 was 7.9%, 5.3% and 25.6% in patients treated with MI belatacept, LI belatacept and CsA, respectively. (Table S4) . Incidence rates of serious infections, any-grade viral infections, any-grade fungal infections and any-grade malignancies per 100 person-years of treatment exposure were generally similar across donor kidney subgroups and treatment arms, although some numerical differences were observed ( Table 2 ). Of the nine cases of posttransplant lymphoproliferative disorder (PTLD) reported prior to month 84, six occurred in patients transplanted with a kidney meeting UNOS ECD criteria, none occurred in the DCD cohort and three occurred in patients who received a kidney with an anticipated CIT ≥24 h (Table 3) .
Discussion
This subgroup analysis of BENEFIT-EXT shows that the efficacy and safety of belatacept-based immunosuppression did not differ in recipients of different extended criteria donor kidney subtypes. Time to death or graft loss was similar between belatacept-and CsA-treated patients in all subgroups. Nevertheless, a statistically significant difference in favor of LI belatacept versus CsA was observed in the DCD cohort (HR 0.095, 95% CI 0.012-0.778; p = 0.0282), but the numbers of patients for this post hoc analysis were small. A study focused on recipients of DCD kidneys may be warranted to determine whether this improvement in survival might be observed in a larger cohort. In general, these findings mirror those derived from the analysis of the overall BENEFIT-EXT population at 7 years after transplant, in which time to death or graft loss was similar for the comparison of CsA with both MI belatacept (HR 0.915, 95% CI 0.625-1.339; p = 0.65) and LI belatacept (HR 0.927, 95% CI 0.634-1.356; p = 0.70) (30) .
Similar to the intent-to-treat analyses performed at 1, 3 and 7 years after transplant for the BENEFIT-EXT (26, 28, 30) and BENEFIT populations (25, 27, 29) , renal function over months 1-84 was significantly greater for belatacept-versus CsA-treated patients across all donor kidney subtypes (p < 0.0001 for overall treatment effect).
The preservation of renal function in belatacept-treated recipients of UNOS ECD kidneys is clinically significant because patients who receive this donor kidney subtype typically have poorer allograft and patient outcomes than recipients of SCD kidneys (31) . In fact, renal dysfunction is an important risk factor for cardiovascular disease, which is the leading cause of death with a functioning graft in kidney transplant recipients (16, 19) . Although it is tempting to speculate that the improvements in renal function seen with belatacept-based immunosuppression may have a positive effect on patient survival, the results of sensitivity analyses examining time to death showed The duration (patient-years) of patient exposure to assigned study drug was calculated from the randomization date to the event date, to the date of last follow-up or to month 84, whichever was earliest. 2 The duration (patient-years) of patient exposure to assigned study drug was calculated from the randomization date to the event date, to the date of last dose of study medication plus 56 days or to month 84, whichever was earliest. no statistically significant differences between belatacept-and CsA-based immunosuppression in either the overall study population (30) or any of the donor kidney subtypes. BENEFIT-EXT, however, was not powered to uncover survival differences between treatment regimens.
Acceptable outcomes with DCD kidneys are possible (and, at best, are similar to those seen in recipients of SCD kidneys) (32) , but recipients of DCD kidneys may experience an increased risk of DGF; however, this has been linked to older donor age (e.g. >50 years) and CIT > 12 h and does not necessarily compromise longer term renal function or patient/graft survival (relative to patients receiving donation after brain death donor kidneys) (32) (33) (34) In the three subgroups, Kaplan-Meier cumulative event rates of AR over the total study period were similar between belatacept-and CsA-based immunosuppression. In addition, Kaplan-Meier cumulative events rates of AR at month 84 were comparable across donor kidney subgroups (UNOS ECD, 15.5-24.9%; DCD, 11.9-26.3%; anticipated CIT ≥24 h, 11.4-19.3%).
At 7 years after transplant in BENEFIT (29) and BENEFIT-EXT (30), the cumulative incidence of de novo DSAs was statistically significantly lower for belatacept-versus CsAbased treatment. Statistically significant differences in favor of belatacept-based immunosuppression were seen in the subgroup of patients transplanted with a UNOS ECD kidney. This finding was not unexpected because the majority (68.9%) of patients in BENEFIX-EXT received a UNOS ECD kidney. It was not possible to analyze de novo DSA incidence in the DCD cohort because of the low number of events (belatacept, n = 0; CsA, n = 3). In the group with anticipated CIT ≥24 h, there was a trend in favor of belatacept-based immunosuppression, but statistical significance was not reached (MI belatacept vs. CsA, p = 0.06; LI belatacept vs. CsA, p = 0.07).
Safety was generally similar across treatment arms and donor kidney subgroups, with no new safety signals.
The absolute incidence of serious AEs ranged from 86.5% to 92.4% in the UNOS ECD cohort, from 78.9%
to 88.9% in the DCD cohort and from 73.0% to 87.5% in the anticipated ≥24 h cohort. The exposure-adjusted incidences of serious infections, any-grade viral infections, any-grade fungal infections and any-grade malignancies were largely similar, but some numerical differences were apparent. Of the nine cases of PTLD reported prior to month 84 in BENEFIT-EXT, six occurred in the UNOS ECD cohort. This is likely due to the fact that the majority of patients in this study received a UNOS ECD kidney rather than a reflection of a predisposition of recipients of this donor kidney subtype to develop PTLD. This supposition is supported by results from a retrospective analysis of the U.S. Renal Data System, which found PTLD incidence to be comparable in patients receiving either a living or deceased donor kidney (35). Due to an increased risk of PTLD, belatacept is not approved for use in patients who are seronegative for Epstein-Barr virus or whose serostatus is unknown prior to transplant.
In terms of limitations, the findings reported in this paper derive from post hoc analyses (p-values are provided for illustrative purposes); therefore, any conclusions drawn should be considered hypothesis generating. Moreover, the DCD cohort was composed of a small number of patients (n = 55), and that limits the conclusions that can be drawn about this donor kidney subtype but highlights the need for additional studies. Despite these limitations, BENEFIT-EXT is the largest prospective study of extended criteria donor kidney recipients treated with non-CNI-based immunosuppression, and the results from this post hoc analysis demonstrate that belatacept is an effective and well-tolerated treatment option for recipients of UNOS ECD kidneys, DCD kidneys or kidneys with an anticipated CIT ≥24 h. 
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